ArticleCancer & metabolism2024
Systemic inflammation and insulin resistance-related indicator predicts poor outcome in patients with cancer cachexia.
Article in Cancer & metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 31 citations in OpenAlex.
- Systemic health impact of cancer-associated extracellular vesicles and particles.Nature reviews. Cancer · 2026Review
- Metabolic-inflammatory index CTI identifies high-risk early-stage natural killer/T-cell lymphoma and informs a novel prognostic model.Biomarker research · 2026Article
- Association between C-reactive protein-triglyceride glucose index (CTI) and cardiovascular and all-cause mortality risk among the elderly population: insights from three datasets.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- C-reactive protein-triglyceride glucose index and its dynamic trajectories on all-cause mortality in critically ill children: a longitudinal, retrospective cohort study.Pediatric research · 2026Article
- Pretreatment C-reactive protein-triglyceride-glucose index predicts survival in patients with FLOT-treated locally advanced gastric and gastroesophageal junction cancer.Oncology letters · 2026Article
- Epigenetic indicators of body mass predict survival outcomes in colorectal cancer patients: patient cohort analysis.Genome medicine · 2026Article
- Association between C-reactive protein-triglyceride glucose index and osteoarthritis in US adults: Evidence from NHANES (2017-2020).Medicine · 2026Article
- Development and validation of a metabolic-inflammatory-nutritional prognostic model for esophageal squamous carcinoma.BMC cancer · 2026Article
- Tumor-induced orexigenic imbalance lowers protein appetite and drives early organ wasting symptoms.Nature communications · 2026Article
- The close relationship between inflammation and insulin resistance: a comparative perspective from a new angle.Acta diabetologica · 2026Article
- Insulin resistance: mechanisms and therapeutic interventions.Molecular biomedicine · 2026Review
- Association of the C-reactive protein-triglyceride-glucose index with liver disease risk: findings from a nationwide Chinese cohort.BMC gastroenterology · 2026Article
- Clinical Significance of the C-Reactive Protein-Triglyceride-Glucose Index in Cardiovascular Disease, Stroke, Cardiovascular-Kidney-Metabolic Syndrome, Cancer, Diabetes, and Osteoporosis: A Narrative Review.International journal of general medicine · 2026Review
- "Paradoxical" prognostic role of the TyG index and a novel machine learning-derived nomogram for colorectal cancer liver metastases.Frontiers in nutrition · 2026Article
- Association of TyG-BMI and malnutrition with reduced survival outcomes in patients with cancer: a prospective study.Frontiers in nutrition · 2026Article
- Association of the hsCRP- triglyceride-glucose index (CTI) with early infarct growth rate in acute ischemic stroke due to large artery occlusion.Frontiers in aging neuroscience · 2026Article
- Joint Association of Inflammatory-Metabolic Indices With Risk of Incident Stroke Among Middle-Aged and Older Chinese Adults.Journal of obesity · 2026Article
- The C-reactive protein-triglyceride glucose index (CTI) predicts mortality in cardiovascular-kidney-metabolic syndrome: a dual-cohort study with machine learning validation.International journal of surgery (London, England) · 2026Article
- Cancer-Associated Cachexia in the Era of Obesity.International journal of molecular sciences · 2025Review
- The relationship between C-reactive protein-triglyceride-glucose index and cardiovascular disease: insights from the China health and retirement longitudinal study (CHARLS).Cardiovascular diabetology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundThe C-reactive protein (CRP)-triglyceride-glucose (TyG) index (CTI), which is a measure representing the level of inflammation and insulin resistance (IR), is related to poor cancer prognosis; however, the CTI has not been validated in patients with cancer cachexia. Thus, this study aimed to explore the potential clinical value of the CTI in patients with cancer cachexia.
methodsIn this study, our prospective multicenter cohort included 1411 patients with cancer cachexia (mean age 59.45 ± 11.38, 63.3% male), which was a combined analysis of multiple cancer types. We randomly selected 30% of the patients for the internal test cohort (mean age 58.90 ± 11.22% 61.4% male). Additionally, we included 307 patients with cancer cachexia in the external validation cohort (mean age 61.16 ± 11, 58.5% male). Receiver operating characteristic (ROC) and calibration curves were performed to investigate the prognostic value of CTI. The prognostic value of the CTI was also investigated performing univariate and multivariate survival analyses.
resultsThe survival curve indicated that the CTI showed a significant prognostic value in the total, internal, and external validation cohorts. Prognostic ROC curves and calibration curves revealed that the CTI showed good consistency in predicting the survival of patients with cancer cachexia. Multivariate survival analysis showed that an elevated CTI increased the risk of death by 22% (total cohort, 95% confidence interval [CI] = 1.13-1.33), 34% (internal test cohort, 95%CI = 1.11-1.62), and 35% (external validation cohort, 95%CI = 1.14-1.59) for each increase in the standard deviation of CTI. High CTI reliably predicted shorter survival (total cohort, hazard ratio [HR] = 1.45, 95%CI = 1.22-1.71; internal test cohort, HR = 1.62, 95%CI = 1.12-2.36; external validation cohort, HR = 1.61, 95%CI = 1.15-2.26). High CTI significantly predicted shorter survival in different tumor subgroups, such as esophageal [HR = 2.11, 95%CI = 1.05-4.21] and colorectal cancer [HR = 2.29, 95%CI = 1.42-3.71]. The mediating effects analysis found that the mediating proportions of PGSGA, ECOG PS, and EORTC QLQ-C30 on the direct effects of CTI were 21.72%, 19.63%, and 11.61%, respectively We found that there was a significant positive correlation between the CTI and 90-day [HR = 2.48, 95%CI = 1.52-4.14] and 180-day mortality [HR = 1.77,95%CI = 1.24-2.55] in patients with cancer cachexia.
conclusionThe CTI can predict the short- and long-term survival of patients with cancer cachexia and provide a useful prognostic tool for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.